Recent studies have demonstrated that YAP/TAZ signaling is constitutively activated in PAVSMCs from patients and experimental models of PAH, promoting cell proliferation and survival, whereas YAP inhibition ameliorates pulmonary arterial remodeling (Kudryashova et al., 2016; Wang et al., 2019; Kudryashova et al., 2022). The gene discussed is YAP1; the disease is pulmonary arterial hypertension.